about
Q fever in French GuianaQ Fever in French Guiana: Tip of the Iceberg or Epidemiological Exception?Climatic drivers of seasonal influenza epidemics in French Guiana, 2006-2010.Comparison between emerging Q fever in French Guiana and endemic Q fever in Marseille, FranceSalmonella enterica serovar Panama meningitis in exclusive breastfeeding infants: Report of 4 cases, clinical features and therapeutic challengesHigh prevalence of HBsAg during pregnancy in Asian communities at Cayenne Hospital, French Guiana.First human rabies case in French Guiana, 2008: epidemiological investigation and control.Later cART initiation in migrant men from sub-Saharan Africa without advanced HIV disease in France.Critical importance of long-term adherence to care in HIV infected patients in the cART era: new insights from Pneumocystis jirovecii pneumonia cases over 2004-2011 in the FHDH-ANRS CO4 cohort.Additive preventive effect of influenza and pneumococcal vaccines in the elderly: results of a large cohort study.Unique clone of Coxiella burnetii causing severe Q fever, French Guiana.Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy.Q fever pneumonia in French Guiana: prevalence, risk factors, and prognostic score.Clinical epidemiology and resistance mechanisms of carbapenem-resistant Acinetobacter baumannii, French Guiana, 2008-2014.[Analgesia after hip fracture repair in elderly patients: the effect of a continuous femoral nerve block: a prospective and randomised study]Molecular epidemiology of Enterobacteriaceae isolates producing extended-spectrum beta-lactamases in a French hospital.Influence of geographic origin, sex, and HIV transmission group on the outcome of first-line combined antiretroviral therapy in France.Prospective evaluation of the SD BIOLINE Dengue Duo rapid test during a dengue virus epidemic.Rainfall and sloth births in may, Q fever in July, Cayenne, French Guiana.AIDS-related Histoplasma capsulatum var. capsulatum infection: 25 years experience of French Guiana.Evolution of fluoroquinolone resistance among Escherichia coli urinary tract isolates from a French university hospital: application of the dynamic regression model.A predictive score for hypotension in patients with confirmed dengue fever in Cayenne Hospital, French Guiana.Cohort Profile: French hospital database on HIV (FHDH-ANRS CO4).Increased incidence of mucosal candidiasis after HAART initiation: a benign form of immune reconstitution disease?A comparison of the pharmacodynamics and pharmacokinetics of bupivacaine, ropivacaine (with epinephrine) and their equal volume mixtures with lidocaine used for femoral and sciatic nerve blocks: a double-blind randomized study.Comparison of the parasacral approach and the posterior approach, with single- and double-injection techniques, to block the sciatic nerve.Body mass index, hypertension and 5-year coronary heart disease incidence in middle aged men: the PRIME study.Low plasma levels of dehydroepiandrosterone sulphate in HIV-positive patients coinfected with hepatitis C virus.[Short term effects of hypertonic saline during severe sepsis and septic shock]Comparison of 3 intensities of stimulation threshold for brachial plexus blocks at the midhumeral level: a prospective, double-blind, randomized study.Boosted protease inhibitor monotherapy as a maintenance strategy: an observational study.Could B-type Natriuretic Peptide (BNP) plasma concentration be useful to predict fluid responsiveness [corrected] in critically ill patients with acute circulatory failure?A comparison of mepivacaine versus lidocaine for episcleral (sub-tenon's) block for cataract surgery in an ambulatory setting.Mortality attributable to nosocomial infection: a cohort of patients with and without nosocomial infection in a French university hospital.Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection.Antibiotic susceptibility determination for six strains of Coxiella burnetii MST 17 from Cayenne, French GuianaDual Nucleoside Reverse Transcriptase Inhibitor Therapy in the Combination Antiretroviral Therapy Era and Predictors of Discontinuation or Switch to Combination Antiretroviral TherapyMaintaining Antiretroviral Therapy Reduces the Risk of AIDS-Defining Events in Patients with Uncontrolled Viral Replication and Profound ImmunodeficiencyDifferential Impact of Combination Antiretroviral Therapy in Preventing Kaposi's Sarcoma With and Without Visceral InvolvementImmunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV
P50
Q26996435-3705BE21-BCF8-4E24-BD43-42487EC5D1FCQ29353616-E1074619-1D44-46B1-9AD0-FA694328333FQ30429566-4B3D4C92-B7BA-4294-A72A-DD8B50820885Q33588548-075E2D5E-9DF6-4263-BD53-61560756D19FQ33672472-F3AAF30E-1141-472F-A29F-D07960440658Q34087505-A5726FD7-430D-4EF5-A3E0-06AF5C8E2E75Q34171796-98B767B6-B8B5-4EC3-8380-3A2B93780ABCQ35143972-045BFD2E-F065-436B-92AA-0176E8362F83Q35146521-DAF7B83C-5AF6-4138-B7F9-A22F6063791AQ36887932-6FC2CA64-EADB-4B19-8260-AE6F1F00049FQ37021114-15944F2A-B01A-48D3-97B3-5C3B3947643FQ38457311-31E94252-7F8E-4EA5-BE0B-18495CF6E513Q38994305-2CC96781-55C3-41F5-BB61-A6F56E4373A6Q39203611-A93EC7F4-324E-4C73-9976-19D60D26D836Q39342859-BCC3BF11-0DCB-47E7-83AC-03331A7CAF70Q39488218-3CB7D004-1A33-4C34-A09A-FEFACB73FAE3Q39590931-63BB4265-444B-4B61-9109-890C30A4340BQ40042292-EC0957FF-215F-4058-8C33-A3E12283B2C6Q40163918-61BC343B-EA7E-4613-84CF-B654ABA597D2Q40417716-7A81A037-9212-4047-95B4-2D88F042FEEAQ40438901-507711D8-424A-4491-A32B-EB33216F41F0Q41929302-00310CB4-DBB2-4F9A-9FDE-9DE7A636E9C0Q42236353-327D67FA-98FE-4865-8F53-3FA56BC2DAECQ43569367-BB3837D7-BEB8-40BD-AC47-30D22EE411F7Q44041484-63406AFB-53F7-42B7-BEF0-47A282F136E1Q44453655-6030B02F-7943-469B-9B10-713F40C7F346Q44672996-93F8D98E-E2F7-4375-B793-AB0AEA0E5405Q44893796-5378BDAB-BEC1-4822-8C0C-268E31A77DD2Q44964334-00747965-2250-4375-B83D-A111A435F701Q45941475-7A3227CB-C9FE-4756-A736-355E665F075BQ46694838-3C020AFA-9051-4140-B120-5F7D02AA3720Q48571801-2714F8B7-4D63-4751-8EE0-79EC8EED9E78Q48698411-0776644C-1B62-4C5A-B5CF-5519424F0804Q51764583-C9E26376-EBC7-4131-A7A2-A5AE44E9A002Q53891501-6A154876-F033-4049-B39B-127342C5B829Q56553919-FA8A615A-CE83-42E9-BEA2-4C6407A5E619Q56762694-499B3C9E-F7D4-403D-B679-5C31E354A0D2Q56837820-4AADBB41-9A34-40BB-869D-B8CD993825EEQ56837833-BD6A422C-97D0-432F-B4CD-1DD76C192CC4Q56837870-33A84D42-2149-4FFC-B0CF-CE53C34AEEE0
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Aba Mahamat
@ast
Aba Mahamat
@en
Aba Mahamat
@es
Aba Mahamat
@nl
Aba Mahamat
@sl
type
label
Aba Mahamat
@ast
Aba Mahamat
@en
Aba Mahamat
@es
Aba Mahamat
@nl
Aba Mahamat
@sl
prefLabel
Aba Mahamat
@ast
Aba Mahamat
@en
Aba Mahamat
@es
Aba Mahamat
@nl
Aba Mahamat
@sl
P214
P106
P21
P214
P31
P496
0000-0001-8755-0424
P569
2000-01-01T00:00:00Z
P735
P7859
viaf-189477063